Effect of shikonin on proliferation, apoptosis, migration and angiogenesis of hemangioma endothelial cell

doi:10.19439/j.sjos.2022.06.003

Abstract

Abstract: PURPOSE: To investigate the effect of shikonin (SKN) on proliferation, apoptosis, migration and angiogenesis of hemangioma endothelial cell (HemEC). METHODS: CCK-8 and EdU assays were used to detect the effect of SKN on proliferation of HemEC. The effect of SKN on apoptosis of HemEC was detected by flow cytometry. Wound healing assay was used to detect the effect of SKN on migration ability of HemEC. The effect of SKN on angiogenesis ability of HemEC was detected by tube formation assay. SPSS 22.0 software package was used for statistical analysis of the data. RESULTS: SKN inhibited proliferation (P<0.001) and promoted apoptosis (P<0.001) of HemEC in a concentration-dependent manner. In additon, SKN inhibited HemEC migration(P<0.01) and angiogenesis(P<0.001). CONCLUSIONS: SKN can inhibit proliferation, migration, angiogenesis and promote apoptosis of HemEC.

Key words: Shikonin, Infantile hemangioma, HemEC, Apoptosis

CLC Number:

R739.8

YANG En-li, WANG Na, LI Ming-yang, LI Yi-ming, GENG Yi-ming, ZHANG Dong-sheng, WU Hai-wei. Effect of shikonin on proliferation, apoptosis, migration and angiogenesis of hemangioma endothelial cell[J]. Shanghai Journal of Stomatology, 2022, 31(6): 576-580.

References

[1] Léauté-Labrèze C, Harper JI, Hoeger PH.Infantile haemangioma[J]. Lancet, 2017, 390(10089): 85-94.
[2] Léauté-Labrèze C, Dumas De La Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008, 358(24): 2649-2651.
[3] 郑家伟, 王绪凯, 秦中平, 等. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识[J]. 上海口腔医学, 2016, 25(3): 257-260.
[4] Chang L, Lv D, Yu Z, et al.Infantile hemangioma: factors causing recurrence after propranolol treatment[J]. Pediatr Res, 2018, 83(1-1): 175-182.
[5] Gomez-Acevedo H, Dai Y, Strub G, et al.Identification of putative biomarkers for infantile hemangiomas and propranolol treatment via data integration[J]. Sci Rep, 2020, 10(1): 3261-3278.
[6] Caussé S, Aubert H, Saint-Jean M, et al.Propranolol-resistant infantile haemangiomas[J]. Br J Dermatol, 2013, 169(1): 125-129.
[7] Xia Y, Wang X, Liu Y, et al.PKM2 is essential for bladder cancer growth and maintenance[J]. Cancer Res, 2022, 82(4): 571-585.
[8] Wang S, Fu J, Hao H, et al.Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy[J]. Pharmacol Res, 2021, 170: 105728.
[9] Boulos JC, Rahama M, Hegazy MF, et al.Shikonin derivatives for cancer prevention and therapy[J]. Cancer Lett, 2019, 459: 248-267.
[10] Laken PA.Infantile hemangiomas: pathogenesis and review of propranolol use[J]. Adv Neonatal Care, 2016, 16(2): 135-142.
[11] Kowalska M, Debek W, Matuszczak E.Infantile hemangiomas: an update on pathogenesis and treatment[J]. J Clin Med, 2021, 10(20): 4631-4643.
[12] 林思, 秦慧真, 邓玲玉, 等. 紫草素抗肿瘤作用研究进展[J]. 中国实验方剂学杂志, 2022, 28(9): 273-282.
[13] 赵莉, 黄景荣, 龚承先, 等. 紫草素对人食管癌TE-1细胞增殖、凋亡和细胞周期的影响及其可能的机制[J].中国肿瘤生物治疗杂志, 2020, 27(8): 889-894.
[14] 马畅, 彭国良, 李妍. 紫草素对乳腺癌4T1细胞增殖的抑制作用及其机制研究[J]. 吉林医药学院学报, 2022, 43(2): 85-87.
[15] 杨志强, 陈路, 张雅茜, 等. 紫草素通过调节PI3K/AKT途径抑制骨肉瘤生长和作用机制研究[J]. 中国比较医学杂志, 2022, 32(1): 68-74, 96.
[16] 刘亚楠, 王炳先, 路臣桂, 等. 紫草素对子宫内膜癌细胞增殖、凋亡和顺铂耐药性的影响[J].中成药, 2021, 43(8): 2219-2224.
[17] Huang J, Zhao L, Gong C, et al.Shikonin promotes apoptosis and attenuates migration and invasion of human esophageal cancer cells by inhibiting tumor necrosis factor receptor-associated protein 1 expression and AKT/mTOR signaling pathway[J]. Evid Based Complement Alternat Med, 2021: 5386050.
[18] Guo C, He J, Song X, et al.Pharmacological properties and derivatives of shikonin-a review in recent years[J]. Pharmacol Res, 2019, 149: 104463.
[19] 朱梦媛, 王汝冰, 周文, 等. 紫草素及其衍生物抗肿瘤作用研究进展[J].药学学报, 2012, 47(5): 588-593.
[20] Zheng H, Huang Q, Huang S, et al.Senescence inducer shikonin ROS-dependently suppressed lung cancer progression[J]. Front Pharmacol, 2018, 9: 519-533.